Despite its extensive use to treat ALK+ NSCLC, the first-generation ALK inhibitor, crizotinib, is not a selective ALK TKI and can inhibit other kinases such as cMET [112,113], which is a potential driver of RT resistance [114]. This evidence concerns the gene ALK and non-small cell lung carcinoma.